{
  "nctId": "NCT04200833",
  "briefTitle": "Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab",
  "officialTitle": "Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab",
  "protocolDocument": {
    "nctId": "NCT04200833",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2021-12-14",
    "uploadDate": "2021-12-14T16:47",
    "size": 198894,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04200833/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [],
  "studyType": "OBSERVATIONAL",
  "enrollmentInfo": {
    "enrollmentCount": 10,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2010-03-01",
    "completionDate": "2021-08-01",
    "primaryCompletionDate": "2021-07-01",
    "firstSubmitDate": "2019-08-06",
    "firstPostDate": "2019-12-16"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* JIA associated Uveitis\n* Treatment failure with adalimumab\n\nExclusion Criteria:\n\n* Uveitis due to other causes\n* Adalimumab Initiation because of non ocular reasons",
    "healthyVolunteers": false,
    "sex": "ALL",
    "stdAges": [
      "CHILD",
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number of Participants Reported as Complete Responders to Golimumab",
        "description": "Response was classified as complete, partial, or none (\"non-response\", NR) at each timepoint separately.\" Complete response (CR) constituted achieving inactive uveitis, defined as 0+ cells in the AC (grade 0). Partial response (PR) was diagnosed in patients with improved uveitis, defined as a decrease in the level of inflammation, without achieving AC grade 0 status. Primary-NR was diagnosed in patients without change in SUN score and an entry grade of 3 or higher or in patients with worsening activity, defined as either a two-grade increase in inflammation or an increase in inflammation to grade 4. Relapse of uveitis was defined as active inflammation after at least 3 months of inactivity,",
        "timeFrame": "last follow up, up to 5 years"
      }
    ],
    "secondary": [
      {
        "measure": "Best Corrected Visual Acuity (BCVA)",
        "description": "best corrected visual acuity",
        "timeFrame": "up to 5 years"
      },
      {
        "measure": "Number of Patients With Ocular Discomfort",
        "description": "eye soreness, photophobia",
        "timeFrame": "up to 5 years"
      },
      {
        "measure": "Steroid Sparing Potential",
        "description": "Reduction in systemic steroid dose at the 12 month follow-up compared to baseline",
        "timeFrame": "Baseline, 12 Months Follow-Up"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 3,
      "otherCount": 0,
      "totalCount": 4
    },
    "studyDesign": {
      "phases": [],
      "isRandomized": false,
      "isMasked": true
    },
    "overallComplexityScore": 44,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:59.347Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}